SATELLOS CHANGES PRIMARY EFFICACY ENDPOINT IN BASECAMP PHASE 2 PEDIATRIC TRIAL TO MRI-MEASURED FAT FRACTION FOLLOWING FDA FEEDBACK

Reuters · 1d ago

Please log in to view news